

ResApp Appoints New Director

Perth, Western Australia, 22 February 2016 -- ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce the appointment of Mr Brian Leedman as a Director of the Company.

Mr Leedman is a co-founder of the Company and currently serves in the role of Vice President, Corporate Affairs. Mr Leedman is a marketing and investor relations professional with over 10 years' experience in the biotechnology/healthcare industry. Prior to ResApp, Mr Leedman co-founded Enigma Therapeutics which listed on the ASX in 2013 as Oncosil Medical Limited. He is also a founding Director of Biolife Science Limited which listed on the ASX as Imugene Limited in 2013. Mr Leedman previously served for 10 years as Vice President, Investor Relations for pSivida Corp. which is listed on the ASX and NASDAQ. He is currently the Western Australian Chair of AusBiotech, the association of biotechnology companies in Australia.

Dr Roger Aston, Chairman of ResApp Health Limited commented, "It is my pleasure to welcome Brian to the Board of ResApp. We have worked together for many years dating back to pSivida. I'm certain through his wealth of experience and passion for the sector, he will be a valuable addition to the Board".

- ENDS -

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

About ResApp Health Limited

ResApp Health Limited, founded in 2014, is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has a multi-site clinical study underway and preliminary results demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children. Approval has been recently received to



extend the study to adults. Markets for ResApp's technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au